New Clinical Trial Results Suggest Surgery with Perioperative Hormone Therapy as Potential Option for High-Risk Prostate Cancer

"A watershed moment" in prostate cancer treatment, according to experts.

PROTEUS Trial: Dual Hormone Therapy Shows Superior Outcomes for High-Risk Prostate Cancer

Results from the phase 3 PROTEUS trial indicate that combining two hormone therapies before and after surgery may be more effective than a single hormone therapy regimen in high-risk, non-metastatic prostate cancer. Some oncologists believe this could establish a new standard of care.

• The PROTEUS trial compared two hormone therapies administered both before and after surgery versus one hormone therapy given before and after surgery in patients with high-risk, early-stage prostate cancer.
• The combined approach showed superior outcomes. The study's results were published and discussed at a medical meeting.

In an editorial in the New England Journal of Medicine, Emmanual Antonarakis, a genitourinary medical oncologist at the University of Minnesota, called the results a "watershed moment" in prostate cancer treatment.